CCA Summit Live from ASCO 2021

Mitesh J. Borad

CCA Summit Live from ASCO 2021

ASCO Highlights

Videos — June 9, 2021

Featuring:

Mitesh J. Borad, MD

Associate Professor of Medicine
Mayo Clinic
Phoenix, AZ

On June 8, 2021, Dr Mitesh Borad, Associate Professor of Medicine at the Mayo Clinic in Phoenix, AZ, and a member of the Cholangiocarcinoma Summit Program Steering Committee, presented the top 15 abstracts on the management of cholangiocarcinoma and biliary tract cancer at ASCO 2021.

Following his presentation, Dr Borad, the other members of the Program Steering Committee, and attendees of the “CCA Summit Live from ASCO 2021” meeting discussed the abstracts and provided their perspectives on these key presentations.

ASCO Highlights

September 2025, Vol 6, No 3

The ADJUBIL trial reveals that dual immune checkpoint blockade with durvalumab and tremelimumab without capecitabine offers a promising adjuvant therapy option with minimal toxicity for resectable biliary tract cancer.

TP53 Mutations in BTC: A Prognostic Marker and a Potential Target for Immune Checkpoint Inhibitors

ASCO Highlights

September 2025, Vol 6, No 3

Patients with TP53-mutated biliary tract cancer may have poorer prognoses but show enhanced responsiveness to immune checkpoint inhibitors, offering hope for tailored therapeutic strategies.

Triplet Immunotherapy in Advanced Hepatocellular and Biliary Tract Cancers

ASCO Highlights

September 2025, Vol 6, No 3

A novel triplet immunotherapy combining durvalumab, bevacizumab, and tremelimumab shows potential for improving survival in advanced hepatocellular and biliary tract cancers.

Rilvegostomig Plus Chemotherapy in Advanced Biliary Tract Cancer

ASCO Highlights

September 2025, Vol 6, No 3

A novel bispecific antibody, rilvegostomig, combined with chemotherapy shows promising efficacy and safety in improving outcomes for patients with advanced biliary tract cancer.

Zanidatamab-hrii Extends Survival in Previously Treated HER2-Positive BTC

ASCO Highlights

September 2025, Vol 6, No 3

Zanidatamab-hrii significantly improves survival in HER2-positive biliary tract cancer, offering new hope for patients with limited second-line treatment options.

Real-World Outcomes of Ivosidenib in IDH1-Mutated CCA: A Study in US Veterans

ASCO Highlights

September 2025, Vol 6, No 3

Real-world data from US veterans confirm the safety and efficacy of ivosidenib in treating IDH1-mutated cholangiocarcinoma, offering hope for improved outcomes in this challenging cancer.

Initial Findings From a Phase 2 Trial on Trifluridine/Tipiracil Combined With Irinotecan as Second-Line Therapy for CCA

ASCO Highlights

September 2025, Vol 6, No 3

The TRITICC trial highlights a promising second-line therapy with trifluridine, tipiracil, and irinotecan for advanced cholangiocarcinoma, offering hope after failure of first-line treatment.

Advancing Early Detection of BTC Using cfDNA Fragmentomics and Machine Learning

ASCO Highlights

September 2025, Vol 6, No 3

A cutting-edge circulating cell-free DNA fragmentomics approach combined with machine learning offers a noninvasive method for early detection of biliary tract cancer.

Results From a Randomized Phase 2 Trial: Addition of SBRT to Systemic Chemotherapy in Locally Advanced CCA (ABC-07)

ASCO Highlights

September 2024, Vol 5, No 3

Efficacy and safety results from the randomized phase 2 ABC-07 trial was presented comparing the addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in patients with locally advanced cholangiocarcinoma (CCA).

The Use of BOLD-100 Alongside FOLFOX Has the Potential to Be a Potent and Well-Accepted Treatment Plan for Advanced Metastatic BTC in Previously Treated Individuals

ASCO Highlights

September 2024, Vol 5, No 3

The phase 2 BOLD-100-001 study evaluated the safety and efficacy of the novel BOLD-100 anticancer drug plus FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer (BTC).

CCA Summit Live from ASCO 2021

Featuring:

Subscribe Today!

I'd like to receive:

Stay In The Know

CCA Summit Live from ASCO 2021

Featuring:

Related Items

Subscribe Today!

I'd like to receive:

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content